Uimyung Research Institute for Neuroscience, Sahmyook University, 26-21 Kongreung-dong, Nowon-gu, Seoul, Korea.
Psychopharmacology (Berl). 2012 May;221(2):217-26. doi: 10.1007/s00213-011-2564-1. Epub 2011 Nov 17.
Methylphenidate is a psychostimulant given for extended periods of time as a treatment of attention-deficit/hyperactivity disorder (ADHD). The long-term effects of the drug are not yet known, and it is speculated that repeated exposure may produce drug dependence.
To investigate the effects of repeated methylphenidate treatment on methylphenidate self-administration and reinstatement in the most validated animal model of ADHD, the spontaneously hypertensive rat (SHR), and Wistar rat, strain representing the "normal" heterogeneous population.
Rats were administered intraperitoneally with saline or methylphenidate (2 mg/kg) for 14 days, prior to experiments. Thereafter, responses for intravenous methylphenidate under the fixed ratio (FR1 and FR3) and progressive ratio (PR) schedules were assessed. Extinction experiments followed, as well as tests to determine the ability of intraperitoneal administration of methylphenidate (2 and 5 mg/kg) to reinstate extinguished drug-seeking behaviors in rats.
Previous exposure to methylphenidate enhanced methylphenidate self-administration in Wistar rats but not in SHR (FR3). Methylphenidate pretreatment reduced responding for methylphenidate in SHR but did not affect self-administration behaviors of Wistar rats (PR). Methylphenidate pre-exposure robustly reinstated drug-seeking behaviors in Wistar rats, but not in SHR.
The contrasting effects of repeated methylphenidate treatment in methylphenidate self-administration and reinstatement in Wistar and SHR, and the increased susceptibility of the Wistar rat strain to the reinforcing effects of methylphenidate indicate that "normal" individuals are more likely to develop psychological dependence to the drug and experience relapse. Meanwhile, the clinical use of methylphenidate may not produce drug dependence or relapse in ADHD patients.
哌醋甲酯作为一种精神兴奋剂,长期用于治疗注意力缺陷多动障碍(ADHD)。该药物的长期效果尚不清楚,据推测,反复暴露可能会产生药物依赖。
在最有效的 ADHD 动物模型——自发性高血压大鼠(SHR)和 Wistar 大鼠中,研究重复哌醋甲酯治疗对哌醋甲酯自我给药和复吸的影响,Wistar 大鼠代表了“正常”的异质人群。
在实验前,给大鼠腹膜内注射生理盐水或哌醋甲酯(2mg/kg)14 天。之后,评估静脉内哌醋甲酯在固定比例(FR1 和 FR3)和逐步比例(PR)计划下的反应。随后进行了消退实验,以及测试腹膜内给予哌醋甲酯(2 和 5mg/kg)是否能恢复已消除的大鼠药物寻求行为。
先前接触哌醋甲酯增强了 Wistar 大鼠对哌醋甲酯的自我给药,但对 SHR 没有影响(FR3)。哌醋甲酯预处理减少了 SHR 对哌醋甲酯的反应,但对 Wistar 大鼠的自我给药行为没有影响(PR)。哌醋甲酯预暴露强烈地恢复了 Wistar 大鼠的药物寻求行为,但对 SHR 没有影响。
在 Wistar 和 SHR 中,重复哌醋甲酯治疗对哌醋甲酯自我给药和复吸的影响不同,以及 Wistar 大鼠对哌醋甲酯的强化作用的易感性增加,表明“正常”个体更有可能对药物产生心理依赖并经历复发。同时,临床使用哌醋甲酯可能不会在 ADHD 患者中产生药物依赖或复发。